Adma Biologics, Inc. (ADMA): Brian Lenz , CFO of Adma Biologics, Inc. purchased 2,500 shares on May 3, 2016. The Insider buying transaction was reported by the company on May 5, 2016 to the Securities and Exchange Commission. The shares were purchased at $6.50 per share for a total value of $16,250.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 5, 2016, Adam S Grossman (CEO) purchased 200,000 shares at $6.50 per share price.On May 5, 2016, Jerrold B Grossman (director) purchased 45,769 shares at $6.50 per share price.Also, On Dec 3, 2015, Brian Lenz (CFO) purchased 1,000 shares at $9.16 per share price.On Mar 18, 2015, Lawrence P. Guiheen (director) purchased 1,000 shares at $7.96 per share price.
Shares of ADMA Biologics Inc (ADMA) ended Wednesday, May 4, 2016 session in red amid volatile trading. The shares closed down -0.23 points or -3.37% at $6.59 with 72,460 shares getting traded. Post opening the session at $6.8, the shares hit an intraday low of $6.42 and an intraday high of $6.8299 and the price vacillated in this range throughout the day. The company has a market cap of $71 M and the number of outstanding shares has been calculated to be 1,07,13,087 shares. The 52-week high of ADMA Biologics Inc is $10.2798 and the 52-week low is $4.15.
ADMA Biologics Inc. is a biopharmaceutical company that develops and manufactures specialty plasma-based biologics for the treatment and prevention of certain infectious diseases. The company’s targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. The Company’s lead product candidate RI-002 is intended for the treatment of primary immune deficiency disease (PIDD). RI-002 is an injectable immune globulin derived from human plasma with levels of naturally occurring polyclonal antibodies as well as levels of antibodies targeted to respiratory syncytial virus (RSV). The company’s RI-002 demonstrated Phase III results and attained its primary endpoint and preliminary analysis indicates that the treatment with RI-002 resulted in no serious bacterial infections (SBI’s) observed in study subjects during the trial.